MX2021007490A - Tratamiento de la hipercoagulopatia en el sindrome de cushing mediante la administracion de moduladores del receptor de glucocorticoides. - Google Patents

Tratamiento de la hipercoagulopatia en el sindrome de cushing mediante la administracion de moduladores del receptor de glucocorticoides.

Info

Publication number
MX2021007490A
MX2021007490A MX2021007490A MX2021007490A MX2021007490A MX 2021007490 A MX2021007490 A MX 2021007490A MX 2021007490 A MX2021007490 A MX 2021007490A MX 2021007490 A MX2021007490 A MX 2021007490A MX 2021007490 A MX2021007490 A MX 2021007490A
Authority
MX
Mexico
Prior art keywords
hypercoagulopathy
cushing
risk
syndrome
methods
Prior art date
Application number
MX2021007490A
Other languages
English (en)
Inventor
Andreas G Moraitis
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of MX2021007490A publication Critical patent/MX2021007490A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se divulgan métodos novedosos para prevenir, reducir el riesgo de desarrollar y tratar la hipercoagulopatía en pacientes con síndrome de Cushing con riesgo elevado de desarrollar hipercoagulopatía. Los métodos son además útiles para prevenir, reducir el riesgo de desarrollar y tratar la trombosis venosa profunda (TVP), la embolia pulmonar (EP) y el tromboembolismo venoso (TEV); y para tratar estados inflamatorios. Los métodos incluyen: administrar un modulador del receptor de glucocorticoides de azadecalina fusionada con heteroaril-cetona (HKGRM) a un paciente con síndrome de Cushing con riesgo de desarrollar hipercoagulopatía, tratando de esta manera la hipercoagulopatía. Los métodos para prevenir, reducir el riesgo de desarrollar y tratar la TVP, RP o TEV en un paciente con síndrome de Cushing comprenden la administración de un HKGRM al paciente. Los métodos para desenmascarar y reducir posteriormente un estado inflamatorio comprenden la administración de una cantidad eficaz de un HKGRM a un paciente con síndrome de Cushing, eficaz primero para aumentar los síntomas inflamatorios y después para disminuir posteriormente dichos síntomas inflamatorios en el paciente.
MX2021007490A 2018-12-21 2019-12-20 Tratamiento de la hipercoagulopatia en el sindrome de cushing mediante la administracion de moduladores del receptor de glucocorticoides. MX2021007490A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862784270P 2018-12-21 2018-12-21
PCT/US2019/067894 WO2020132469A1 (en) 2018-12-21 2019-12-20 Treatment of hypercoagulopathy in cushing's syndrome by administration of glucocorticoid receptor modulators

Publications (1)

Publication Number Publication Date
MX2021007490A true MX2021007490A (es) 2021-08-05

Family

ID=71098284

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007490A MX2021007490A (es) 2018-12-21 2019-12-20 Tratamiento de la hipercoagulopatia en el sindrome de cushing mediante la administracion de moduladores del receptor de glucocorticoides.

Country Status (11)

Country Link
US (2) US11524013B2 (es)
EP (1) EP3897654A4 (es)
JP (1) JP7309883B2 (es)
KR (1) KR20210095939A (es)
CN (1) CN113194957A (es)
AU (1) AU2019404416A1 (es)
CA (1) CA3122583A1 (es)
IL (1) IL284263A (es)
MX (1) MX2021007490A (es)
SG (1) SG11202105765TA (es)
WO (1) WO2020132469A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210095939A (ko) * 2018-12-21 2021-08-03 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제의 투여에 의한 쿠싱 증후군의 과응고병증의 치료
MX2021010135A (es) 2019-02-22 2021-09-23 Corcept Therapeutics Inc Usos terapeuticos de relacorilante, un modulador del receptor de glucocorticoides de azadecalina fusionada con heteroaril-cetona.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2532350A1 (en) * 2007-10-17 2012-12-12 Laboratoire HRA Pharma Pharmaceutical combination of a glucocorticoid receptor antagonist and a cortisol synthesis inhibitor for treating cushing's syndrome
GB2477256B (en) 2008-11-07 2013-12-25 Univ Sheffield Determination of predisposition towards subclinical Cushing's syndrome or incidentaloma
KR20180008627A (ko) * 2015-05-18 2018-01-24 코어셉트 쎄라퓨틱스, 잉크. 쿠싱 증후군을 진단하고 이에 대한 치료를 평가하는 방법
EP3335043B1 (en) 2015-08-13 2021-03-31 Corcept Therapeutics, Inc. Method for differentially diagnosing acth-dependent cushing's syndrome
KR20210095939A (ko) * 2018-12-21 2021-08-03 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제의 투여에 의한 쿠싱 증후군의 과응고병증의 치료
MX2021010135A (es) * 2019-02-22 2021-09-23 Corcept Therapeutics Inc Usos terapeuticos de relacorilante, un modulador del receptor de glucocorticoides de azadecalina fusionada con heteroaril-cetona.

Also Published As

Publication number Publication date
KR20210095939A (ko) 2021-08-03
US20200197411A1 (en) 2020-06-25
JP2022516024A (ja) 2022-02-24
US11524013B2 (en) 2022-12-13
AU2019404416A1 (en) 2021-06-10
IL284263A (en) 2021-08-31
WO2020132469A1 (en) 2020-06-25
CA3122583A1 (en) 2020-06-25
US20230097191A1 (en) 2023-03-30
SG11202105765TA (en) 2021-07-29
JP7309883B2 (ja) 2023-07-18
EP3897654A4 (en) 2022-09-07
EP3897654A1 (en) 2021-10-27
CN113194957A (zh) 2021-07-30

Similar Documents

Publication Publication Date Title
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MX2021007490A (es) Tratamiento de la hipercoagulopatia en el sindrome de cushing mediante la administracion de moduladores del receptor de glucocorticoides.
SG191334A1 (en) Use of a vegf antagonist to treat angiogenic eye disorders
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
JOP20200156A1 (ar) إيسكيتامين لعلاج الاكتئاب
JOP20200082A1 (ar) علاج متلازمة الكروموسوم إكس الهش باستخدام الكانابيديول
MD3883606T2 (ro) Metodă sigură și eficientă de tratament al colitei ulcerative cu anticorpi anti-IL12/IL23
WO2018209022A3 (en) Methods of treating neuropsychiatric disorders
CO2018007165A2 (es) Terapia génica para tratar hipercolesterolemia familiar
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
MX2016000220A (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
EA201991650A1 (ru) Способы лечения неврологических расстройств
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
MX2018009867A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
MX2021001549A (es) Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera.
MX2016006256A (es) Tratamiento de glaucoma usando laquinimod.
WO2017123667A3 (en) Non-ischemic heart failure treatment by cell therapy
MX2021012848A (es) Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn.
MX2021007076A (es) Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
EA201592058A1 (ru) Применение ландиолола гидрохлорида в длительном лечении тахиаритмии
MX2021005189A (es) Uso de tivozanib para tratar sujetos con cancer refractario.
EA201491545A1 (ru) Способ лечения гиперхолестеринемии